Five New Agents with OS Benefits Approved Since Study Initiation Radium-223 Abiraterone acetate (Chemo-naïve-302) Enzalutamide (Post-chemo) Abiraterone acetate (Post-chemo-301) Cabazitaxel Sipuleucel-T Docetaxel Abiraterone acetate (Chemo-naïve-302) Enzalutamide (Post-chemo) Sipuleucel-T Abiraterone acetate a (Post-chemo-301) Cabazitaxel Docetaxel US approvals EU approvals Radium-223 200520042006200720082009201020112012201420152013 FPI LPI COU-AA-302 FPI, first patient in; LPI, last patient in Enzalutamide (Chemo-naive) a Hereafter referred to as abiraterone Ryan C et al.
{}